Curaleaf Holdings (CURA) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 216.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: -0.11%
• EPS Growth: 11.22%
• Country: CA
• Employees: 5,519
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.10
• Shares Outstanding: 670,192,500
• 10 Day Avg. Volume: 289,633
• 30 Day Avg. Volume: 216,057
• PEG Ratio: 0.31
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.38
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 2.56
• Enterprise Value/Ebitda: 1.61
• 1Y Price Target: $5.24
• Price Target Upside: 279.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: C$1.50 ▲(8.70%Upside)

Curaleaf Holdings' stock score is primarily influenced by financial performance challenges and valuation concerns. While technical analysis and earnings call sentiment provide some optimism, profitability and leverage issues weigh heavily on the overall score.

Positive Factors

Market Expansion

Expansion into new markets is anticipated to increase revenue streams.

Operational Efficiency

Operational efficiencies are expected to drive margins.

Sales Growth

Sales growth in 2Q24 was largely driven by wholesale revenue growth as the international segment continues to gain traction.

Negative Factors

Competition

The company is facing stiff competition in the cannabis industry.

Financial Performance

EBITDA margins fell short of expectations due to higher G&A spend and heavy promotions at the start of the quarter.

Regulatory Challenges

There are concerns about regulatory challenges in the cannabis market.

Curaleaf Holdings Business Overview & Revenue Model

Company Description

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In addition, it offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. Further, the company provides hemp-based CBD and cannabigerol products. The company was founded in 2010 and is headquartered in New York, New York.

How the Company Makes Money

Curaleaf Holdings generates revenue primarily through the sale of cannabis products across its retail dispensaries and wholesale channels. The company's key revenue streams include the direct sale of proprietary branded products, such as Curaleaf, Select, and Grassroots, which are available in various forms including flower, pre-rolls, oils, and edibles. Additionally, Curaleaf earns revenue through wholesale operations where it supplies cannabis products to other dispensaries and retailers. Strategic partnerships and acquisitions also play a vital role in expanding Curaleaf's market presence and product offerings, contributing to its earnings. The company's vertically integrated model ensures control over the entire supply chain, from cultivation to distribution, optimizing cost efficiencies and product quality.

Curaleaf Holdings Financial Statement Overview

Summary

Curaleaf Holdings faces challenges with profitability due to declining revenues and persistent net losses. Despite improvements in cash flow and operational efficiency, high debt levels pose financial stability concerns. Focus on enhancing profitability and managing leverage is needed.

Income Statement

The company shows a declining revenue trend with a slight drop in total revenue from $1.34 billion in the previous year to $1.31 billion in TTM. The gross profit margin has decreased, indicating increased cost pressures. Furthermore, negative net income results in a negative net profit margin, highlighting ongoing profitability challenges. Though EBIT and EBITDA margins show slight improvements, they remain low, impacting overall profitability.

Balance Sheet

The balance sheet shows a relatively high debt-to-equity ratio, which poses leverage risks. However, the equity ratio remains stable, suggesting a moderate level of equity financing. Return on equity is negative due to net losses, impacting shareholder returns. Overall, the balance sheet shows stability but with notable leverage risks.

Cash Flow

Operating cash flow remains positive, reflecting operational viability. The free cash flow has grown compared to previous periods, improving cash flow stability. However, the free cash flow to net income ratio is affected by persistent losses, and the operating cash flow to net income ratio indicates inefficiencies. Overall, cash flow management shows improvements but remains constrained by net income losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.34B	1.35B	1.34B	1.21B	626.64M
Gross Profit	639.25M	614.45M	579.03M	687.59M	390.51M
EBITDA	233.14M	238.76M	220.97M	278.98M	128.59M
Net Income	-215.42M	-281.20M	-376.93M	-109.13M	-61.33M
Balance Sheet
Total Assets	2.95B	3.10B	3.41B	3.11B	2.39B
Cash, Cash Equivalents and Short-Term Investments	93.03M	91.82M	163.18M	299.33M	73.54M
Total Debt	853.82M	883.55M	931.91M	652.40M	577.71M
Total Liabilities	1.96B	1.93B	2.01B	1.44B	1.01B
Stockholders Equity	861.21M	1.05B	1.28B	1.55B	1.38B
Cash Flow
Free Cash Flow	64.42M	5.05M	-91.96M	-205.92M	-113.92M
Operating Cash Flow	162.57M	75.26M	46.40M	-33.96M	12.36M
Investing Cash Flow	-93.83M	-78.69M	-228.62M	-163.97M	-197.11M
Financing Cash Flow	-54.24M	-67.02M	50.54M	424.80M	224.08M

Curaleaf Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Neutral. The current price of 1.38 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.21, and below the 200-day MA of 2.04, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 56.62 is Neutral, neither overbought nor oversold. The STOCH value of 32.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:CURA.

Curaleaf Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CURA	60 Neutral	$1.05B	―	-25.08%	―	-0.11%	11.22%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
CGC	―	$227.29M	―	-122.10%	―	―	―
ACB	―	$251.58M	94.51	3.05%	―	―	―
CRON	―	$771.54M	16.05	4.61%	―	―	―
TCNNF	―	$794.71M	―	-12.39%	―	―	―
CRLBF	―	$237.64M	―	-17.34%	―	―	―

Curaleaf Holdings Corporate Events

Curaleaf to Announce Q2 2025 Financial Results

Curaleaf Holdings announced it will release its second quarter 2025 financial and operational results on August 6, 2025, after market close. The announcement will be followed by a conference call and webcast, providing stakeholders with insights into the company’s performance and strategic direction. This release is significant for stakeholders as it offers an opportunity to gauge Curaleaf’s market positioning and operational progress in the evolving cannabis industry.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Acquires Full Ownership of European Operations

Curaleaf Holdings has acquired the remaining equity stake in Curaleaf International Holdings Limited from a strategic institutional investor, bringing its ownership to 100%. This acquisition, completed through a Put/Call Option agreement, allows Curaleaf to streamline decision-making and enhance strategic alignment across its European operations, reinforcing its commitment to international expansion and long-term shareholder value.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Strengthens Leadership with New President and Key Executive Hires

Curaleaf Holdings has appointed Rahul Pinto as the new President to lead its global commercial functions, alongside strengthening its leadership team with three new Senior Vice Presidents in digital, retail merchandising, and brand marketing. This strategic move aims to enhance Curaleaf’s position as a global leader in the cannabis industry by leveraging Pinto’s extensive experience in consumer packaged goods and retail, as well as the expertise of the new hires, to drive innovation and growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Confirms Board and Auditor at 2025 AGM

Curaleaf Holdings, Inc. recently held its 2025 Annual General Meeting of Shareholders, where key resolutions were passed, including the election of ten directors and the reappointment of PKF O’Connor Davies, LLP as the company’s auditor. The meeting, conducted via webcast, saw significant shareholder participation with over 1.7 billion votes cast. These decisions are expected to reinforce Curaleaf’s governance and operational strategies, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Strengthens Governance at 2025 Annual Meeting

Curaleaf Holdings, Inc. held its 2025 Annual General Meeting of Shareholders via webcast, where key resolutions were passed, including the election of directors and the reappointment of the company’s auditor. The meeting saw a significant number of votes cast, reflecting strong shareholder engagement. These developments are expected to reinforce Curaleaf’s governance and operational stability, positively impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Reports Q1 2025 Results with Strong International Growth

Curaleaf Holdings reported a total revenue of $310 million for the first quarter of 2025, with a notable international revenue growth of 74% year-over-year. Despite a decrease in net revenue compared to the previous year, the company achieved a 50% adjusted gross margin and continued to expand its product offerings and retail locations, demonstrating resilience and strategic positioning for long-term success.